- Home
- SNDX vs JBGS Comparison
SNDX vs JBGS Comparison
Compare SNDX & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- JBGS
- Stock Information
- Founded
- SNDX 2005
- JBGS 2016
- Country
- SNDX United States
- JBGS United States
- Employees
- SNDX N/A
- JBGS N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- JBGS Real Estate Investment Trusts
- Sector
- SNDX Health Care
- JBGS Real Estate
- Exchange
- SNDX Nasdaq
- JBGS Nasdaq
- Market Cap
- SNDX 1.3B
- JBGS 1.4B
- IPO Year
- SNDX 2016
- JBGS 2017
- Fundamental
- Price
- SNDX $13.51
- JBGS $21.35
- Analyst Decision
- SNDX Strong Buy
- JBGS Sell
- Analyst Count
- SNDX 11
- JBGS 2
- Target Price
- SNDX $38.55
- JBGS $17.00
- AVG Volume (30 Days)
- SNDX 3.3M
- JBGS 590.4K
- Earning Date
- SNDX 11-03-2025
- JBGS 10-28-2025
- Dividend Yield
- SNDX N/A
- JBGS 3.28%
- EPS Growth
- SNDX N/A
- JBGS N/A
- EPS
- SNDX N/A
- JBGS N/A
- Revenue
- SNDX $77,933,000.00
- JBGS $513,301,000.00
- Revenue This Year
- SNDX $629.90
- JBGS N/A
- Revenue Next Year
- SNDX $114.74
- JBGS $2.33
- P/E Ratio
- SNDX N/A
- JBGS N/A
- Revenue Growth
- SNDX 2126.66
- JBGS N/A
- 52 Week Low
- SNDX $8.58
- JBGS $13.28
- 52 Week High
- SNDX $22.50
- JBGS $24.30
- Technical
- Relative Strength Index (RSI)
- SNDX 36.63
- JBGS 50.50
- Support Level
- SNDX $13.00
- JBGS $20.19
- Resistance Level
- SNDX $15.79
- JBGS $21.86
- Average True Range (ATR)
- SNDX 1.10
- JBGS 0.55
- MACD
- SNDX -0.26
- JBGS 0.12
- Stochastic Oscillator
- SNDX 13.82
- JBGS 72.87
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.